



**Tuesday, 15 May 2018**

---

Break  
08:00 - 09:30

Foyer

**Registration and Welcome Coffee**

Plenary Session  
09:30 - 10:00

Congress Hall

**Welcome Address**

**CIMT President Christoph Huber**

**09:30 - 10:00**

Plenary Session  
10:00 - 11:30

Congress Hall

**Cellular Therapy**

Chair: Harpreet Singh (Immatics Biotechnologies, Houston, United States)

**New modes of T-cell cancer recognition by dissection of immunotherapy successes**

**10:00 - 10:30**

Speaker: Andrew Sewell (Cardiff University, Cardiff, United Kingdom)

**ADAPting to solid tumors, advances and challenges for TCR T-cell therapy**

**10:30 - 11:00**

Speaker: Gwen Binder-Scholl (Adaptimmune, Philadelphia, United States)

**TIL therapy in melanoma: history of clinical development, current status and plans for the future**

**11:00 - 11:30**

Speaker: Rodabe Amaria (University of Texas MD Anderson Cancer Center, Houston, United States)

Break  
11:30 - 13:30

Foyer

**Lunch**

Corporate Supported Symposium  
12:00 - 13:00

Congress Hall

**"Immunooncology 2018 and beyond" supported by Bristol-Myers Squibb**

Chair: Dirk Jäger (National Center for Tumor Diseases, Heidelberg, Germany)

<b>Immunooncology from mono- to combination therapy - a clinical perspective</b>	<b>12:00 - 12:20</b>
Speaker: Viktor Grünwald (Medical School Hannover (MHH), Hanover, Germany)	
<b>Resistance to immunotherapy</b>	<b>12:20 - 12:40</b>
Speaker: Guy Ungerechts (National Center for Tumor Diseases, Heidelberg, Germany)	
<b>Biomarkers in immunooncology - can we predict the outcome of therapy?</b>	<b>12:40 - 13:00</b>
Speaker: Andreas Jung (Ludwig-Maximilians-Universität, Munich, Germany)	

Plenary Session  
13:30 - 15:00

Congress Hall

### Counteracting Immune Escape

Chair: Cornelis Melief (ISA Pharmaceuticals, Leiden, Netherlands)  
Chair: Thorbald van Hall (Leiden University Medical Center, Leiden, Netherlands)

<b>TNFR family members and cancer immunotherapy: lessons from chronic infection</b>	<b>13:30 - 14:00</b>
Speaker: Tania Watts (University of Toronto, Toronto, Canada)	
<b>Role of lymphatic vessels in shaping the tumor immune microenvironment</b>	<b>14:00 - 14:30</b>
Speaker: Melody Swartz (University of Chicago, Chicago, United States)	
<b>Regulation of dendritic cells in tumors</b>	<b>14:30 - 15:00</b>
Speaker: Jan P. Böttcher (Technical University Munich, Munich, Germany)	

Break  
15:00 - 16:00

Foyer

### Coffee Break

Poster Session  
15:30 - 18:00

East and West Foyers

### Poster Session - Therapeutic Vaccination

<b>Reinforcing dendritic cells for cancer immunotherapy: diverse ways and means to target antigens to human skin</b>
Speaker: Lydia Bellmann (Medical University of Innsbruck, Innsbruck, Austria)
<b>A versatile, high-throughput HLA peptidomics pipeline for cancer neoepitope discovery</b>
Speaker: Leon Bichmann (Uni-Tuebingen, Tuebingen, Germany)
<b>Targeted LC-MS detection identifies novel immunogenic HLA-A2-restricted T cell epitopes derived from HPV16 E6 and E7</b>
Speaker: Maria Bonsack (German Cancer Research Center (DKFZ), Heidelberg, Germany)
<b>Predicting observed patient responses to a short-peptide cancer vaccine via clinical trial simulations</b>
Speaker: Liam V Brown (University of Oxford, Oxford, United Kingdom)
<b>The Glioma Actively Personalized Vaccine Consortium (GAPVAC) presents the successful clinical translation of mutated peptide vaccination</b>
Speaker: Valesca Bukur (Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany)

**HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients**

Speaker: Luigi Buonaguro (Istituto Nazionale Tumori Pascale, Napoli, Italy)

**Dendritic cell-targeted nano-vaccines synergize with anti-PD-1/anti-OX40 for melanoma treatment**

Speaker: Joao Conniot (Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal)

**Molecular mechanism of immune cell activation by therapeutic melanoma vaccine**

Speaker: Patrycja Czerwińska (Poznań University of Medical Sciences, Poznań, Poland)

**A cancer vaccine targeting many neo-antigens is required for efficient eradication of large tumors**

Speaker: Maria De Lucia (University of Naples Federico II, Naples, Italy)

**Successful completion of the Mutanome Engineered RNA Immuno-Therapy (MERIT) project**

Speaker: Katrin Frenzel (BioNTech Group, Mainz, Germany)

**Bifunctional RNA-nanoparticles to enhance dendritic cell activation and enable MRI-based detection of dendritic cell migration to lymph nodes**

Speaker: Adam Grippin (University of Florida Brain Tumor Immunotherapy Program, Gainesville, United States)

**E6/E7 RNA(LIP): An RNA cancer vaccine for treatment of patients with HPV16-positive malignancies**

Speaker: Christian Grunwitz (Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany)

**A novel rMVA combination immunotherapy triggers potent innate and adaptive immune responses against established tumors**

Speaker: Maria Hinterberger (Bavarian Nordic, Planegg, Germany)

**A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma**

Speaker: Robert A. Jabulowsky (BioNTech AG, Mainz, Germany)

**Novel linear doggybone™ DNA vaccine induces anti-tumour immunity via STING and independent of TLR9**

Speaker: Cinderella Jawahar (University of Southampton, Southampton, United Kingdom)

**Nucleic Acid based TRL ligand loaded nanocomplexes act as standalone antitumor agents**

Speaker: G. Gokberk Kaya (Bilkent University, Ankara, Turkey)

**Discovery and vaccine development for hepatocellular carcinoma - HEPAVAC**

Speaker: Markus W. Löffler (University of Tübingen, Tübingen, Germany)

**Retrospective analysis of neoantigen prediction methods**

Speaker: Martin Löwer (TRON-Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz gGmbH, Mainz, Germany)

**Modulating T cell immunity in tumors by targeting PD-L1 and neoantigens using a live attenuated oral Salmonella platform**

Speaker: Heinz Lubenau (VAXIMM GmbH, Mannheim, Germany)

**Enrichment of gene modified cellular melanoma vaccines with melanoma stem cells or inducible pluripotent stem cells increases immunogenicity and clinical effectiveness in mice**

Speaker: Andrzej Mackiewicz (Poznań University of Medical Sciences, Poznań, Poland)

**The immunopeptidomic landscape of breast cancer**

Speaker: Ana Marcu (University of Tuebingen, Tuebingen, Germany)

**Multivalent polymeric nanoparticles for combinatorial innovative colorectal cancer immunotherapy and immunomodulation**

Speaker: Ana Isabel Matos (Instituto de Investigação do Medicamento (iMed.Ulisboa), Faculdade de Farmácia da Universidade de Lisboa, Lisboa, Portugal)

**Ibrutinib in combination with T-cell based immunotherapy in chronic lymphocytic leukemia (CLL) - mass spectrometry-based HLA ligandome analysis of primary CLL cells approves stable presentation of leukemia-associated antigens**

Speaker: Annika Nelde (University of Tübingen, Institute for Cell Biology, Tübingen, Germany)

**Nanoparticle-based vaccine improved OX40 anti-tumor efficacy in breast cancer**

Speaker: Carina Peres (Research Institute for Medicines (iMed.Ulisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal)

**Analysis of the human tumor HLA peptidome based on patient derived xenografts in mice**

Speaker: Nataly Rijensky (Technion-Israel Institute of Technology, Haifa, Israel)

**Pseudocowpox (PCPV): a viral vector for cancer immunotherapy**

Speaker: Karola Rittner (Transgene, Illkirch-Graffenstaden, France)

**Local radiotherapy and E7-RNA-LPX vaccination activate non-redundant mechanisms and lead to complete tumor rejection of well-established HPV16+ TC-1 tumors**

Speaker: Nadja Salomon (TRON, Mainz, Germany)

**Standard therapy supplemented with immunogenic cell death therapy during and subsequent multimodal immunotherapy for GBM**

Speaker: Stefaan Van Gool (IOZK, Köln, Germany)

**NKG2A blockade potentiates CD8+ T-cell immunity induced by cancer vaccines**

Speaker: Thorbald van Hall (Leiden University Medical Center, Leiden, Netherlands)

**Biomaterial-based scaffolds improve delivery of therapeutic nanoparticle cancer vaccines to dendritic cells**

Speaker: Jorieke Weiden (Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands)

**Exosomes co-encapsulating antigen and immunoadjuvants act as an effective therapeutic cancer vaccine**

Speaker: Muzaffer Yildirim (Bilkent University, Ankara, Turkey)

Poster Session  
15:30 - 18:00

East and West Foyers

**Poster Session - Immunomonitoring**

**Evaluation of immunological changes induced by primary treatment in ovarian cancer patients**

Speaker: Thuy Linh Eline Achten (Katholieke Universiteit Leuven, Leuven, Belgium)

**Prognostic relevance of immunological changes during first line treatment in epithelial ovarian carcinoma**

Speaker: Thaïs Baert (KU Leuven, Leuven, Belgium)

**Peripheral blood NKT-cell frequencies and their PD-1 expression levels identify stage IV melanoma patients with poor overall survival under PD-1/CTLA-4 blockade**

Speaker: Jonas Bochem (University Medical Center Tübingen, Tübingen, Germany)

**T cell Elispot proficiency panel 2017/2018: Evaluating routine T cell Elispot assays**

Speaker: Liselotte Brix (Immudex, Copenhagen, Denmark)

**MHC class II Dextramers - A new tool for detection of antigen specific CD4+ T-cells**

Speaker: Liselotte Brix (Immudex, Copenhagen, Denmark)

**High-throughput screening of human tumor-antigen specific CD4 T cells, including neo-antigen reactive cells**

Speaker: Carla Costa-Nunes (Translational Tumor Immunology Group, Department of fundamental Oncology, University of Lausanne, Epalinges, Switzerland)

**Rapid Target Identification for T-Cell Immune Responses with SpotMix™ Peptide Pools**

Speaker: Maren Eckey (JPT Peptide Technologies GmbH, Berlin, Germany)

**MemoMAB: Gateway to human antibody repertoires**

Speaker: Christoph Esslinger (Memo Therapeutics AG, Zurich, Switzerland)

**CetuGEX and Cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC) - p16+ subgroup analysis of the phase 2 RESGEX study**

Speaker: Beate Habel (Glycotope GmbH, Berlin, Germany)

**High dimensional analysis of the myeloid cell landscape in human breast cancer metastatic lymph nodes**

Speaker: Rodrigo Nalio Ramos (Institute Curie, Paris, France)

**Tumor infiltrating T cells: complete workflows allow faster and improved flow cytometric analysis of syngeneic mouse tumors**

Speaker: Anne Richter (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

**New and reproducible method for rapid, standardized PBMC preparation and cryoconservation within the scope of clinical trials**

Speaker: Anne Richter (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

**Conventional and immune therapies influence the immune microenvironment of malignant brain tumors**

Speaker: Matteo Riva (KU Leuven, Leuven, Belgium)

**The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival**

Speaker: Saskia J.A.M. Santegoets (Leiden University Medical Center, Leiden, Netherlands)

**An improved in vitro assay for monitoring antigen-specific T cell responses using synthetic 20mer peptides**

Speaker: Juliane Schneider (University of Tübingen, Tübingen, Germany)

**The spleen functions as a window of a systemic response to detect responders to immune checkpoint inhibitor treatment in murine progressed solid carcinomas by [18F]FDG positron emission tomography (PET)**

Speaker: Barbara F. Schoerg (Eberhard Karls University Tuebingen, Tuebingen, Germany)

**Metabolic profiling of secondary lymphatic organs using 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/CT together with eosinophil blood count, S100 and LDH levels is applicable to stratify patients with metastatic melanomas responding to checkpoint inhibitor immunotherapy (CIT)**

Speaker: Johannes Schwenck (Eberhard Karls University Tuebingen, Tübingen, Germany)

**Development of an imperacer (Immuno-PCR) assay combining broad assay range and excellent sensitivity to support development of a TNF-receptor agonist antibody drug**

Speaker: Mark Spengler (Chimera Biotec, Bremen, Germany)

**Ultra sensitive PK bioanalysis in support of the development of a bi-specific immune-recruiting biotherapeutic**

Speaker: Mark Spengler (Chimera Biotec, Bremen, Germany)

**Bioanalytical PK support for Immunotherapeutics: case studies**

Speaker: Mark Spengler (Chimera Biotec, Bremen, Germany)

**Finally, empty HLA class I proteins! A disulfide-stabilized variant of HLA-A\*02:01**

Speaker: Sebastian Springer (Jacobs University Bremen, Bremen, Germany)

**Empty MHC class I molecules: An alternate, convenient, and improved detection tool for antigen specific T cells**

Speaker: Tripti Tamhane (Technical University of Denmark, Lyngby, Denmark)

**Immunomonitoring for personalized cancer immunotherapies via ex vivo combinatorial workflow and concurrent high-resolution class I & II ICS**

Speaker: Alexander Ulges (Immatics Biotechnologies GmbH, Tübingen, Germany)

**Scalable end-to-end immune repertoire analysis: the ImmunoGenomiX Platform**

Speaker: Henk Jan van den Ham (Enpicom, 's Hertogenbosch, Netherlands)

**Tumor epitope detection in monocytes (EDIM) as a marker for antitumoral activity of Newcastle disease virus infusion and modulated electrohyperthermia**

Speaker: Stefaan Van Gool (IOZK, Köln, Germany)

**Peripheral blood  $\gamma\delta$  T-cell frequencies correlate with overall survival of stage IV melanoma patients under PD-1 blockade**

Speaker: Kilian Wistuba-Hamprecht (University Medical Center Tübingen, Tübingen, Germany)

**Disappearance of NY-ESO-1 and Melan-A-specific T-cells from peripheral blood is associated with clinical response in melanoma patients undergoing anti-PD-1 therapy**

Speaker: Henning Zelba (University Medical Center Tübingen, Tübingen, Germany)

Poster Session  
15:30 - 18:00

East and West Foyers

**Poster Session - Tumor Biology and Interaction with the Immune System**

**Monitoring of T cell infiltration and positioning in colorectal cancer liver metastases using a human tissue-based ex vivo cell migration analysis model**

Speaker: Anna Berthel (German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany)

**CD47 expression predicts efficacy of macrophage-mediated phagocytosis of tumor cells**

Speaker: Kira Böhmer (Crown Bioscience Inc., San Diego, United States)

**The oncometabolite R-2-hydroxyglutarate suppresses T cell immunity in IDH1-mutant gliomas**

Speaker: Theresa Bunse (German Cancer Research Center, Heidelberg, Germany)

**Tumoral MHC class II expression in gliomas**

Speaker: Lukas Bunse (German Cancer Research Center (DKFZ), Heidelberg, Germany)

**Role of 14F7 monoclonal antibody immunoreactivity against N-glycolyl GM3 ganglioside in colon cancer prognostic**

Speaker: Adanays Calvo (National Institute of Oncology and Radiobiology, Havana, Cuba)

**Human recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) produced by Lactococcus lactis bacteria acts synergistically with 5-Fluorouracil and Metformin to induce apoptosis in colon cancer cells in vitro**

Speaker: Katarzyna Ciacma (Jagiellonian University Medical College, Kraków, Poland)

**Protumoral effects of TLR7 in lung tumors**

Speaker: Isabelle Cremer (INSERM UMRS1138, Paris, France)

**Durable response to PD-1 blockade in a patient with mismatch repair deficient advanced biliary tract cancer**

Speaker: Elena Czink (National Centre for Tumor Diseases, Heidelberg, Germany)

**Dominant oncolysis in a syngeneic lung cancer model treated with LCMV-GP - pseudotyped vesicular stomatitis virus**

Speaker: Krishna Das (Medical University Innsbruck, Innsbruck, Austria)

**A 3D image-based quantification of tumor-immune cell interactions in the presence of immuno-modulators**

Speaker: Lidia Daszkiewicz (Ocello, Leiden, Netherlands)

**Targeting Stat3 oncogene addiction together with anti PD-1 antibodies as an effective combination for cancer immunotherapy**

Speaker: Mara De Martino (IBYME-CONICET, Buenos Aires, Argentina)

**Epigenetic modifications upregulate PD-1, CTLA-4, TIM-3 and LAG-3 immune checkpoint genes in breast tumor microenvironment**

Speaker: Eyad Elkord (Qatar Biomedical Research Institute, Doha, Qatar)

**CD200 mimetic PEG-M49 and doxorubicin co-treatment increases CD4CD8 double positive cells in CD200R1 knockout mice and the levels correlate with its anti tumoral effects**

Speaker: Nuray Erin (Akdeniz University, Antalya, Turkey)

**The effects of TRPV1 agonists on immune response to metastatic breast cancer as well as on tumor growth and metastasis**

Speaker: Nuray Erin (Akdeniz University, Antalya, Turkey)

**VSV-GP therapy is effective in HNSCC though direct tumor lysis and stimulation of an anti-tumor immune response**

Speaker: Patrik Erlmann (ViraTherapeutics, Innsbruck, Austria)

**Adipose tissue drives accumulation and activation of mast cells in human cancer specimens**

Speaker: Dyke Ferber (National Center for Tumor Diseases (NCT), Heidelberg, Germany)

**IL27R $\alpha$  deficiency alters stromal cell architecture and delays tumor growth in a polyoma middle T oncoprotein-driven breast cancer model**

Speaker: Annika Fink (Goethe-University Frankfurt, Frankfurt, Germany)

**Induction of myeloid-derived suppressor cells via tumor-derived extracellular vesicles in malignant melanoma**

Speaker: Viktor Fleming (German Cancer Research Center (DKFZ), Heidelberg, Germany)

**The safety, tolerability, and preliminary clinical activity of the CXCR4 inhibitor X4P-001 and nivolumab in renal cell carcinoma patients that are refractory to nivolumab monotherapy**

Speaker: Tracy L. Rose (Lineberger Comprehensive Cancer Center, Chapel Hill, United States)

**Single-cell transcriptome analysis unveils a heterogeneous and dynamic landscape of tumor infiltrating CD8 T cells**

Speaker: David Gfeller (University of Lausanne, Epalinges, Switzerland)

**c-MET dependent neutrophil responses limit cancer immunotherapy**

Speaker: Nicole Glodde (University of Magdeburg, Magdeburg, Germany)

**The association between the local immunological microenvironment and the local microbiome in colorectal cancer liver metastases**

Speaker: Silke Grauling-Halama (National Center for Tumor Diseases, Heidelberg, Germany)

**MDSC and neutrophil recruitment and function in melanoma primary and metastatic lesions**

Speaker: Christopher Groth (Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany)

**Size matters: The novel immune checkpoint CEACAM1-3S isoform drives NK cell-mediated cytotoxicity and overall survival in melanoma patients**

Speaker: Iris Helfrich (Medical Faculty, University Duisburg-Essen, Essen, Germany)

**Oncogene-specific T cells fail to eradicate lymphoma-initiating B cells**

Speaker: Dana Hoser (Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany)

**Role of tumor-derived extracellular vesicles in immunosuppression in malignant melanoma patients**

Speaker: Xiaoying Hu (Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Heidelberg, Germany, Mannheim, Germany)

**Targeting CD70-positive cancer associated fibroblasts to tackle the immune suppressive tumor microenvironment in colorectal cancer**

Speaker: Julie Jacobs (University of Antwerp, Wilrijk, Belgium)

**The macrophage immune checkpoint CD47 is a direct target of EMT transcription factors SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT**

Speaker: Bassam Janji (Luxembourg Institute of Health, Luxembourg, Luxembourg)

**Therapy resistance in renal cell carcinoma correlates with an endothelial cell dependent altered immune cell infiltrate**

Speaker: Eva Juengel (Universitätsmedizin Mainz, Mainz, Germany)

**B cells and the antibody response in melanoma: mechanisms of immune modulation and translational opportunities**

Speaker: Sophia N Karagiannis (King's College London, London, United Kingdom)

**In vivo siRNA knockdown of Wnt1 rescues dendritic cells from b-catenin activation and sensitizes tumors to vaccination**

Speaker: Dimitra Kerdidani (BSRC Fleming, Vari, Greece)

**Indoleamine 2,3-dioxygenase 1 (IDO1) in human T cells is inducible upon T cell activation and type I interferons**

Speaker: Raphael Tobias Kfuri Rubens (Ludwig-Maximilians Universität München, Munich, Germany)

**RIG-I-like helicases signaling induced alteration of myeloid-derived suppressor cells phenotype and function unleashes tumor immune control in murine pancreatic cancer**

Speaker: Sabrina Viktoria Kirchleitner (Ludwig-Maximilians-Universität München, Munich, Germany)

**Cytomegalovirus infection leads to c-MET overexpression, adversely affecting survival and resistance to Temozolomide in glioblastoma**

Speaker: Harald Krenzlin (Gutenberg-Universität Mainz, Mainz, Germany)

**Investigating the feasibility of tumour infiltrating lymphocyte therapy for paediatric malignancies with high risk and poor prognosis**

Speaker: Gray Kueberuwa (University of Manchester, Manchester, United Kingdom)

**Omental fat in ovarian cancer induces lymphangiogenesis**

Speaker: Benedicte Lenoir (University Heidelberg, Heidelberg, Germany)

**Pancreatic tumor-derived factors induce expansion of myeloid cells with high suppressive capacity**

Speaker: Philipp Metzger (Klinikum der Universität München, München, Germany)

**Investigation of ICOS expression on human and mouse T cell subsets**

Speaker: Ramona Murr (Roche Innovation Center Zurich, Schlieren-Zuerich, Switzerland)

**Acute myeloid leukemia (AML) promotes generation of iTregs**

Speaker: Anya Nikolai (Loyola University Chicago, Maywood, United States)

**Urokinase type Plasminogen Activator and Beta-galactoside alpha 2,6 sialyltransferase 1 found in cancer cell exosomes cause autocrine release of CXCR2 ligands**

Speaker: Nur Ogan (Akdeniz University, Antalya, Turkey)

**Investigation of effects of MSCs on immunoevasive adaptations of breast tumor cell lines, MDA-MB-231 and MCF-7**

Speaker: Alper Tunga Özdemir (Ege University, Institute of Health Sciences, Izmir, Turkey)

**The effects of mesenchymal stem cell on the macrophage phenotype**

Speaker: Bilge Özdemir (Manisa State Hospital, Manisa, Turkey)

**Expression of MHC class I determines the prognostic benefit of tumor-infiltrating T cells in ovarian cancer independent of the PD-1/PD-L1 axis**

Speaker: Sterre Paijens (University of Groningen, Groningen, Netherlands)

**Uncovering miRNAs that affect melanoma cell recognition and killing by antigen specific CD8+ T cells**

Speaker: Antonino A. Pane (DKFZ, Heidelberg, Germany)

**Manipulation of potassium channels in tumor specific T cells for improved functionality in the suppressive tumor microenvironment**

Speaker: Sara Ram Pedersen (Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, Herlev, Denmark)

**Evidence for T-cell mediated immunity of HPV vaccination by 3-colour fluorescent EliSpot assay**

Speaker: Rosemarie Preyer (GenID GmbH, Straßberg, Germany)



**Upregulation of HLA class I expression, CIITA-related block of HLA class II expression and heterogenous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches**

Speaker: Elise Ramia (University of Insubria, Varese, Italy)

**Live-cell assays for immune cell killing of 3D tumour spheroids**

Speaker: Annedore Respa (Essen Bioscience, Welwyn Garden City, United Kingdom)

**The Role of RAF-MAPK signalling in Dendritic cells**

Speaker: Kristina Riegel (Mainz University Medical Center/MSU-FZI, Mainz, Germany)

**The anatomical location determines type of lymphocyte infiltration in tumors of same etiology**

Speaker: Saskia J.A.M. Santegoets (Leiden University Medical Center, Leiden, Netherlands)

**Oncogenic BRAFV600E governs regulatory T cell recruitment during melanoma tumorigenesis**

Speaker: Tamer Basel Shabaneh (Geisel School of Medicine at Dartmouth, Lebanon, United States)

**Pan-cancer analysis of human endogenous retrovirus expression reveals markers for prognosis and immunotherapy response in clear cell renal carcinoma**

Speaker: Christof Chiu Smith (UNC - Chapel Hill, Chapel Hill, United States)

**Omental fat-induced immune alterations during metastatic spreading of epithelial ovarian cancer: insights from tissue explant culture**

Speaker: Meggy Suarez-Carmona (University Hospital Heidelberg, Heidelberg, Germany)

**Characterization of rarely detectable tumor-associated antigens (TAA)-specific CD8+ T cells in HCC patients**

Speaker: Catrin Tauber (University Hospital Freiburg, Freiburg, Germany)

**Increased replication and spread of the oncolytic VSV-GP in a syngeneic prostate cancer model does not correlate with improved therapeutic outcome**

Speaker: Carles R. Urbiola (Medical University Innsbruck, Innsbruck, Austria)

**Myeloid derived suppressor cells (MDSC) determine outcome in ovarian cancer**

Speaker: Ann Vankerckhoven (KU Leuven, Leuven, Belgium)

**Molecular mechanisms responsible for CCR5 regulation on MDSC in melanoma**

Speaker: Rebekka Weber (University Medical Center Mannheim, Mannheim, Germany)

**Tumor microenvironment T-cell repertoire and mutational load are independently associated with the outcome of sequential checkpoint inhibition in melanoma**

Speaker: Erik Yusko (Adaptive Biotechnologies, Seattle, United States)

**History of prior immunotherapy changes relationship between tumor mutations and TIL repertoire**

Speaker: Erik Yusko (Adaptive Biotechnologies, Seattle, United States)

Plenary Session  
18:00 - 19:00

Congress Hall

**Keynote Lecture**

Chair: Christoph Huber (CIMT, Mainz, Germany)

**Highly multiplex 2D and 3D imaging of the immune system and tumors**

**18:00 - 19:00**

Speaker: Ronald Germain (NIAD, NIH, Bethesda, United States)

Plenary Session  
08:00 - 09:30

Congress Hall

### Tumor Microenvironment

Chair: Viktor Umansky (German Cancer Research Center DKFZ, Heidelberg, Germany)  
Chair: Günter Hämmerling (German Cancer Research Center DKFZ, Heidelberg, Germany)

**Potent and durable tumor immunity induced by ADU-S100, a first-in-class STING agonist** 08:00 - 08:30

Speaker: Andrea van Elsas (Aduro Biotech, Oss, Netherlands)

**The Ying and Yang of TAM: Macrophages as effector cells for cytotoxic antibodies in vivo** 08:30 - 09:00

Speaker: Falk Nimmerjahn (Friedrich-Alexander-University, Erlangen, Germany)

**Myelopoiesis and cancer: "Flipping" over monocytes into immune suppressive cells** 09:00 - 09:30

Speaker: Vincenzo Bronte (University of Verona, Verona, Italy)

Break  
09:30 - 10:00

Foyer

### Coffee Break

Short Talk Session  
10:00 - 11:30

Congress Hall

### Short Talk Session I Tumor Biology and Interaction with the Immune System

Chair: Hansjörg Schild (Institute for Immunology at the University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany)  
Chair: Steve Pascolo (University Hospital Zurich, Zurich, Switzerland)

**Monitoring of T cell infiltration and positioning in colorectal cancer liver metastases using a human tissue-based ex vivo cell migration analysis model** 10:00 - 10:15

Speaker: Anna Berthel (German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany)

**The oncometabolite R-2-hydroxyglutarate suppresses T cell immunity in IDH1-mutant gliomas** 10:15 - 10:30

Speaker: Theresa Bunse (German Cancer Research Center, Heidelberg, Germany)

**Single-cell transcriptome analysis unveils a heterogeneous and dynamic landscape of tumor infiltrating CD8 T cells** 10:30 - 10:45

Speaker: David Gfeller (University of Lausanne, Epalinges, Switzerland)

**In vivo siRNA knockdown of Wnt1 rescues dendritic cells from b-catenin activation and sensitizes tumors to vaccination** 10:45 - 11:00

Speaker: Dimitra Kerdidani (BSRC Fleming, Vari, Greece)

**RIG-I-like helicases signaling induced alteration of myeloid-derived suppressor cells phenotype and function unleashes tumor immune control in murine pancreatic cancer** 11:00 - 11:15

Speaker: Sabrina Viktoria Kirchleitner (Ludwig-Maximilians-Universität München, Munich, Germany)

**Tumor microenvironment T-cell repertoire and mutational load are independently associated with the outcome of sequential checkpoint inhibition in melanoma** **11:15 - 11:30**  
Speaker: Erik Yusko (Adaptive Biotechnologies, Seattle, United States)

Short Talk Session  
10:00 - 11:30

Gutenberg Hall A

### Short Talk Session II Cellular Therapy

Chair: Sébastien Wälchli (Oslo University Hospital, Oslo, Norway)  
Chair: Isabel Poschke (German Cancer Research Center DKFZ, Heidelberg, Germany)

**The recognition patterns of T cell receptors identified using peptide-MHC multimers labeled with DNA barcodes** **10:00 - 10:15**  
Speaker: Amalie Kai Bentzen (Technical University of Denmark, Lyngby, Denmark)

**In vivo generation of CD4+ and CD8+ CAR-T cells by receptor-targeted lentiviral vectors** **10:15 - 10:30**  
Speaker: Julia D. S. Hanauer (Paul-Ehrlich-Institut, Langen, Germany)

**Neoantigen-specific CD8 T cells are structurally and functionally overlapping with CD8 T cells recognizing shared self-tumor and viral epitopes** **10:30 - 10:45**  
Speaker: Morgane Magnin (Lausanne University Hospital Centre (CHUV), Epalinges, Switzerland)

**Super-resolution microscopy dSTORM reveals CD19dim expression on a subset of myeloma cells that can be targeted with CD19-CAR T cells** **10:45 - 11:00**  
Speaker: Thomas Nerreter (Universitätsklinikum Würzburg, Würzburg, Germany)

**Off-target toxicity risk evaluation for TCR-based therapies guided by immunopeptidomics data of a comprehensive set of more than 650 primary normal tissue samples** **11:00 - 11:15**  
Speaker: Heiko Schuster (Immatix Biotechnologies GmbH, Tübingen, Germany)

**Intestinal graft-versus-host disease is driven by BATF-dependent IL-7RhiGM-CSF+ T cells** **11:15 - 11:30**  
Speaker: Evelyn Ullrich (Johann Wolfgang Goethe-University, Children's Hospital, Frankfurt, Germany)

Short Talk Session  
10:00 - 11:30

Gutenberg Hall B

### Short Talk Session III New Targets & New Leads

Chair: John Castle (Agenus Inc, Lexington, United States)  
Chair: Angelika Riemer (German Cancer Research Center DKFZ, Heidelberg, Germany)

**Identification of a naturally presented myeloma-associated BCMA peptide as an immunogenic T-cell epitope for immunotherapeutic approaches** **10:00 - 10:15**  
Speaker: Tatjana Bilich (University of Tübingen, Institute for Cell Biology, Tübingen, Germany)

**Immunopeptidomic profiling of triple negative breast cancer identifies potential immunotherapy target antigens** **10:15 - 10:30**  
Speaker: Demin Li (University of Oxford, Oxford, United Kingdom)

**KY1055: a novel ICOS/PD-L1 bispecific antibody, enhances T cell activation and delivers potent monotherapy anti-tumour responses in vivo** **10:30 - 10:45**  
Speaker: Matthew McCourt (Kymab, Cambridge, United Kingdom)

<b>Glyco-engineering of an anti-CD40 antibody enhances its agonistic activity</b>	<b>10:45 - 11:00</b>
Speaker: Phillip Schiele (GlycoTope GmbH, Berlin, Germany)	
<b>Database matching of de novo sequencing candidates - a new strategy for MHC peptide identification</b>	<b>11:00 - 11:15</b>
Speaker: Andreas Schlosser (Universität Würzburg, Würzburg, Germany)	
<b>Theranostic tumor imaging of neuroblastoma using radiolabeled <math>\alpha</math>CD276-antibody</b>	<b>11:15 - 11:30</b>
Speaker: Dominik Sonanini (Eberhard Karls University of Tübingen, Tübingen, Germany)	

Break  
11:30 - 14:00

Foyer

## Lunch

Plenary Session  
12:00 - 13:30

Congress Hall

## CAR T-Cell Therapy organized by CARAT

Chair: Christian Buchholz (Paul-Ehrlich-Institut, Langen, Germany)  
Chair: Andrew Kaiser (Miltenyi Biotech, Bergisch Gladbach, Germany)

<b>Chimeric antigen receptor T cells: advances in cellular engineering and clinical development</b>	<b>12:00 - 12:30</b>
Speaker: Bruce Levine (University of Pennsylvania, Philadelphia, United States)	
<b>T-cell engineering for cancer applications</b>	<b>12:30 - 13:00</b>
Speaker: Martin Pule (University College London, London, United Kingdom)	
<b>Cell therapy between academic research and company driven drug development</b>	<b>13:00 - 13:30</b>
Speaker: Peter Borchmann (University Hospital of Cologne, Cologne, Germany)	

Plenary Session  
14:00 - 15:30

Congress Hall

## Combination Therapies

Chair: Sjoerd H. van der Burg (Leiden University Medical Center, Leiden, Netherlands)  
Chair: Dirk Jäger (National Center for Tumor Diseases, Heidelberg, Germany)

<b>Stromal activation in cancer immunology and immunotherapy</b>	<b>14:00 - 14:30</b>
Speaker: Shannon Turley (Genentech, San Francisco, United States)	
<b>Mechanistic insights into the immune adjuvant effect of radiotherapy</b>	<b>14:30 - 15:00</b>
Speaker: Sandra Demaria (Weill Cornell Medical College, New York, United States)	
<b>The anti-TGF<math>\beta</math> neutralizing antibody, SAR439459, blocks immunosuppression and exhibits anti-tumor activity in combination with anti-PD1</b>	<b>15:00 - 15:30</b>
Speaker: Jack Pollard (Sanofi Oncology, Cambridge, United States)	

## Coffee Break

## Poster Session - Cellular Therapy

### **The CliniMACS Prodigy® and CliniMACS® Electroporator platforms enable automated and GMP-compliant production of dendritic cell vaccines**

Speaker: Caroline Angerer (Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany)

### **The recognition patterns of T cell receptors identified using peptide-MHC multimers labeled with DNA barcodes**

Speaker: Amalie Kai Bentzen (Technical University of Denmark, Lyngby, Denmark)

### **LP-141 CliniMACS Prodigy System: primary cross-presenting DCs for the generation of cancer vaccines**

Speaker: Eva Bergschneider (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

### **Automated cell processing and electroporation for generation and genetic engineering of monocyte-derived dendritic cells**

Speaker: Eva Bergschneider (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

### **Exploring human T lymphocytes redirected to the tumor neoantigen EGFRvIII for adoptive cellular immunotherapy of non-small cell lung cancer**

Speaker: Anita Bhatti (University Medical Center Mainz, Mainz, Germany)

### **The development of human $\gamma\delta$ -T antigen presenting cells as a clinical grade cancer vaccine**

Speaker: Miroslava Blahova (University of Birmingham Medical School, Birmingham, United Kingdom)

### **In vitro generation of tumor antigen-specific T cells from patient and healthy donor stem cells**

Speaker: Sarah Bonte (Ghent University, Ghent, Belgium)

### **Automated ex vivo expansion of low numbers of tumor-reactive T cells on the CliniMACS Prodigy®**

Speaker: Elvira Criado-Moronati (Miltenyi Biotec, Bergisch Gladbach, Germany)

### **Nanobody based dual specific CARs**

Speaker: Stijn De Munter (Ghent University, Gent, Belgium)

### **Molecular mechanisms regulating TCR affinity-improved T cells against the NY-ESO-1 tumor antigen**

Speaker: Efe Erdes (Lausanne University Hospital Centre (CHUV), Epalinges, Switzerland)

### **Balancing CD28 costimulation and CD3 $\zeta$ activation in CD19 CAR T cells enhances therapeutic potency by delaying T cell differentiation and exhaustion**

Speaker: Judith Feucht (Memorial Sloan Kettering Cancer Center, New York City, United States)

### **Selecting CD8-specific DARPins for T lymphocyte-directed gene delivery**

Speaker: Annika Melanie Frank (Paul Ehrlich Institute, Langen, Germany)

### **The effect of anti-CTLA-4 blockade on the expansion of tumor-infiltrating lymphocytes for adoptive cell therapy in metastatic ovarian cancer**

Speaker: Christina Friese (Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, Herlev, Denmark)

### **In vivo generation of CD4+ and CD8+ CAR-T cells by receptor-targeted lentiviral vectors**

Speaker: Julia D. S. Hanauer (Paul-Ehrlich-Institut, Langen, Germany)

### **Intracerebral immunomodulation using genetically engineered mesenchymal stem cells induces long-term survival and immunity in glioblastoma**

Speaker: Daniela Hirsch (apceth Biopharma GmbH, Munich, Germany)

**Affinity maturation and validation of a COL6A3-002-specific T cell receptor for improving performance in adoptive cell therapy**

Speaker: Meike Hutt (Immatix Biotechnologies GmbH, Tuebingen, Germany)

**CD4 T-cell based immunotherapy of cancer**

Speaker: Else Marit Inderberg (Oslo University Hospital- The Norwegian Radium Hospital, Oslo, Norway)

**Substantially enhanced CAR-gene transfer rates by CD4- and CD8-targeted lentiviral vectors while retaining selectivity**

Speaker: Arezoo Jamali (Paul Ehrlich Institute, Langen, Germany)

**Best chimeric antigen receptor (CAR) expressing vehicle: peripheral versus tumour infiltrating lymphocytes**

Speaker: Milena Kalaitidou (University of Manchester, Manchester, United Kingdom)

**Adoptive immunotherapy using DNA-demethylated Th-cells as antigen presenting cells induces tumor regression in patients with relapsed glioblastoma**

Speaker: Alexei F. Kirkin (CytoVac A/S, Hørsholm, Denmark)

**Selective bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor therapy**

Speaker: Sebastian Kobold (Klinikum der Universität München, München, Germany)

**Arming T cells with C-X-C-motive receptor 6 enables adoptive T cell therapy of cancer**

Speaker: Sebastian Kobold (Klinikum der Universität München, München, Germany)

**Murine-human hybrid tyrosinase reactive T-cell receptor increases antigen reactivity and cytokine production**

Speaker: Yi Wei Lim (Loyola University Chicago, Chicago, United States)

**PD-L1-specific immunocytokines augment functionality and antitumor activity of CAR-engineered NK cells**

Speaker: Aline Lindner (Georg-Speyer-Haus, Frankfurt am Main, Germany)

**Development of a chimeric costimulatory receptor to enhance CAR T therapy**

Speaker: Dominik Lock (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

**Neoantigen-specific CD8 T cells are structurally and functionally overlapping with CD8 T cells recognizing shared self-tumor and viral epitopes**

Speaker: Morgane Magnin (Lausanne University Hospital Centre (CHUV), Epalinges, Switzerland)

**“Built-in” PD-1 Blockade: a strategy to counteract inhibition of effector cells for adoptive cell cancer therapy**

Speaker: Nadia Mensali (Oslo University Hospital Radiumhospitalet, Oslo, Norway)

**T cells isolated from patients with checkpoint inhibitor resistant-melanoma are functional and can mediate tumor regression**

Speaker: Özcan Met (University Hospital Herlev, Copenhagen, Herlev, Denmark)

**Donor-specific immunomodulation by clinical MIC cell infusion - a phase I study (TOL-1)**

Speaker: Christian Morath (Kidney Center Heidelberg, Heidelberg, Germany)

**Development of flow cytometric assays for CAR T cell manufacturing and patient immunomonitoring**

Speaker: Marsilius Mues (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

**Super-resolution microscopy dSTORM reveals CD19dim expression on a subset of myeloma cells that can be targeted with CD19-CAR T cells**

Speaker: Thomas Nerretter (Universitätsklinikum Würzburg, Würzburg, Germany)

**Induction of tolerogenic dendritic cells in vitro by mitomycin C-induced peripheral blood mononuclear cells**

Speaker: Ming Ni (University Clinic Heidelberg, Heidelberg, Germany)

**In vitro expanded tumor-infiltrating lymphocytes across various sarcoma subtypes highly express LAG3 and comprise multifunctional T cells with tumor killing capacity**

Speaker: Morten Nielsen (Center for Cancer Immune Therapy, Herlev University Hospital, Herlev, Denmark)

**Ex vivo generation and expansion of CAR-engineered NK cells for adoptive cancer immunotherapy**

Speaker: Pranav Oberoi (Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany)

**CD19 splicing and mutation linked to CART-19 immunotherapy resistance**

Speaker: Claudia Paret (Medical University of Mainz, Mainz, Germany)

**T Cell Receptor/DAP10 chimera as a means to attaining persistent anti-tumor T cell response**

Speaker: Lourdes Plaza-Rojas (Loyola University Chicago, Maywood, United States)

**Optimal-affinity T cell receptors targeting NY-ESO via MHC II help MHC I-restricted T cell receptors in tumour regression**

Speaker: Lucia Poncette (Max Delbrück Center for Molecular Medicine, Berlin, Germany)

**Heterogeneity and dynamics of the tumor-infiltrating lymphocyte repertoire in melanoma and pancreatic cancer patients**

Speaker: Isabel Poschke (German Cancer Research Center DKFZ, Heidelberg, Germany)

**Immunotherapy of ovarian cancer by targeting Claudin-6 with CAR-engineered T cells**

Speaker: Katharina Reinhard (BioNTech Cell & Gene Therapies GmbH, Mainz, Germany)

**Update on the clinical trial preparations concerning a MAGE-A1-specific T cell receptor**

Speaker: Vivian Scheuplein (Max-Delbrück-Centrum, Berlin, Germany)

**Off-target toxicity risk evaluation for TCR-based therapies guided by immunopeptidomics data of a comprehensive set of more than 650 primary normal tissue samples**

Speaker: Heiko Schuster (Immatics Biotechnologies GmbH, Tübingen, Germany)

**TCR-pMHC 2D affinity and bond lifetime under force correlate with tumor-specific CD8 T cell responsiveness**

Speaker: Julien Schmidt (University of Lausanne, Epalinges, Switzerland)

**Modifying melanoma immune microenvironment by heterologous prime-boost vaccination with adenovirus and modified vaccinia Ankara virus vectors**

Speaker: Naveen Shridhar (University Clinic Magdeburg, Magdeburg, Germany)

**How to make a fishing rod for adoptive cellular therapy: the ACTolog® approach, a multi-targeted endogenous T-cell therapy**

Speaker: Stefanie Souczek (Immatics Biotechnologies GmbH, Tuebingen, Germany)

**PI3K $\delta$  inhibition by idelalisib for optimized generation of CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients**

Speaker: Sophia Stock (University Hospital Heidelberg, Heidelberg, Germany)

**Enhancing cancer immunotherapy using responsive biomaterials**

Speaker: Li Tang (École polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland)

**Intestinal graft-versus-host disease is driven by BATF-dependent IL-7RhiGM-CSF+ T cells**

Speaker: Evelyn Ullrich (Johann Wolfgang Goethe-University, Children's Hospital, Frankfurt, Germany)

**Enhancing the activation and releasing the brakes of NK cells for treatment of Multiple Myeloma**

Speaker: Evelyn Ullrich (Johann Wolfgang Goethe-University, Children's Hospital, Frankfurt, Germany)

**Combining conventional therapy with immunotherapy: a risky business?**

Speaker: Ann Vankerckhoven (KU Leuven, Leuven, Belgium)

**A two chain chimeric antigen receptor (CAR) scaffold recruits T-cell endogenous CD3 subunits for physiological CAR signaling and induces efficient tumor cell killing in vitro and in vivo**

Speaker: Matthias Birtel (TRON - Translational Oncology at the University Medical Center Mainz gGmbH, Mainz, Germany)

Speaker: Ralf-Holger Voss (University Medical Center (UMC) of the Johannes Gutenberg University Mainz, Mainz, Germany)

**Depletion of macrophages in the tumor-draining lymph node enhances dendritic cell-induced anti-tumor immunity**

Speaker: Heleen Vroman (Erasmus MC, Rotterdam, Netherlands)

**Trapping TGF- $\beta$  with decoy receptors restricts TGF- $\beta$  mediated immune cell suppression**

Speaker: Aleksandra Vuchkovska (Loyola University Chicago, Maywood, United States)

**Pre-clinical validation of a TCR redirected universal NK cell line**

Speaker: Sébastien Wälchli (Oslo University Hospital, Oslo, Norway)

**Inhibition of IL-10 secretion in CAR-engineered NK cells modulates polarization of bystander macrophages and enhances dendritic cell maturation**

Speaker: Anja Waldmann (Georg-Speyer-Haus, Frankfurt, Germany)

**A new cellular immunotherapy for the treatment of multiple myeloma without development of graft-versus-host disease**

Speaker: Sofi Yado (Ariel University, Ariel, Israel)

**Quantitative live-cell imaging as an efficient tool for the assessment of safety and efficacy of engineered T cells and bispecific molecules**

Speaker: Sara Yousef (Immatics biotechnologies GmbH, Tübingen, Germany)

**Preclinical characterization of an off-the-shelf chimeric antigen receptor-engineered NK cell therapeutic for adoptive cancer immunotherapy**

Speaker: Congcong Zhang (Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany)

Poster Session  
15:30 - 18:30

East and West Foyers

**Poster Session - Improving Immunity**

**Mouse models of pancreatic cancer for development of combinatorial immunotherapies involving cytostatic agents and agonist anti-CD40 antibody**

Speaker: Daniel Baumann (German Cancer Research Center (DKFZ), Heidelberg, Germany)

**Role of the Interleukin-33/ ST2L-axis for the CD8-dependent anti-cancer cytotoxicity - Protease- versus receptor-dependent regulation of Interleukin-33 bioactivity**

Speaker: Caroline Dreis (Goethe University, pharmazentrum Frankfurt, Frankfurt/ Main, Germany)

**Targeted immunotherapy with oncolytic measles virus vaccines**

Speaker: Christine E. Engeland (National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany)

**Fc effector function contributes to the activity of human anti-CTLA-4 antibodies**

Speaker: Andrew Furness (Royal Marsden NHS Foundation Trust, London, United Kingdom)

**High rate of objective anti-tumor response in 9 patients with primary or recurrent glioblastoma after viro-immunotherapy with oncolytic parvovirus H-1 in combination with bevacicumab and PD-1 checkpoint blockade**

Speaker: Karsten Geletneky (Klinikum Darmstadt, Darmstadt, Germany)

**Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable treatment of solid tumors with T cell therapies**

Speaker: Riikka Havunen (University of Helsinki, Helsinki, Finland)

**Intratatumoral RNA treatment: a promising approach for the therapy of solid tumors**

Speaker: Katja Fiedler (CureVac AG, Tübingen, Germany)

**Human interleukin-2 (IL-2)/anti-IL-2 antibody complexes preferentially stimulate effector cells and show strong efficacy in tumor models**

Speaker: Andreas Katopodis (Novartis Institutes of Biomedical Research, Basel, Switzerland)

**Abrogation of the immunosuppressive tumor microenvironment in cholangiocarcinoma by targeting PD-1 or GITR**

Speaker: Jaap Kwekkeboom (Erasmus MC University Medical Center, Rotterdam, Netherlands)



**Investigation of combined immune checkpoint blockade in human malignant pleural mesothelioma**

Speaker: Elly Marcq (University of Antwerp, Antwerp, Belgium)

**Activin-A protects against lung cancer progression by potentiating anti-tumor immunity**

Speaker: Ioannis Morianos (Biomedical Research Foundation of the Academy of Athens, Athens, Greece)

**Rapid generation of peptide-HLA complexes with disulfide-stabilized empty HLA-A\*02 molecules for high throughput screening approaches**

Speaker: Andreas Moritz (Immatics biotechnologies, Tübingen, Germany)

**Type I IFN responsiveness of melanoma is cell state dependent and can be both harnessed and suppressed to enhance oncolytic virotherapy efficacy**

Speaker: Janne Ruotsalainen (University Hospital Magdeburg, Magdeburg, Germany)

**Immunomodulatory properties of the glyco-engineered anti-EGFR antibody Tomuzotuximab**

Speaker: Phillip Schiele (GlycoTope GmbH, Berlin, Germany)

**dermaject® intradermal injection device ensures superficial and reproducible intradermal injections in human ex vivo skin**

Speaker: Sandra Schulz (Hahn-Schickard, Villingen-Schwenningen, Germany)

**Loss of myeloid cell GCN2 drives progression in experimental melanomas during immune checkpoint inhibition**

Speaker: Jana K. Sonner (German Cancer Research Center DKFZ, Heidelberg, Germany)

**Dissecting the synergistic effect of chemotherapy and immunotherapy on anti-tumoral T cell functions in breast cancer**

Speaker: Lorenzo Spagnuolo (Oncode Institute, Netherland Cancer Institute, Amsterdam, Netherlands)

**An improved preclinical immuno-oncology platform: Patient-derived tumor xenografts in humanized NSG-SGM3 mice**

Speaker: Ralph Gareus (The Jackson Laboratory, Bar Harbor, United States)

Poster Session  
15:30 - 18:30

East and West Foyers

**Poster Session - New Targets & New Leads**

**The AA protein-based model explains how cancer could arise**

Speaker: Adouda Adjiri (Setif-1 University, Setif, Algeria)

**Peptide-based immune system engagers targeting  $\alpha 3$  integrin prevent tumor growth and metastasis in a syngeneic triple-negative 4T1 tumor model**

Speaker: Mona Ali Mahmoud Assar (University Hospital RWTH Aachen, Aachen, Germany)

**Discovery and validation of highly specific T-cell receptors for Immatics's immunotherapeutic applications**

Speaker: Leonie Alten (Immatics Biotechnologies GmbH, Tuebingen, Germany)

**Identification and profiling of PX-D26116, a potent Hydroxyamidine-based IDO1 inhibitor**

Speaker: Simon Anderhub (Phenex Pharmaceuticals AG, Heidelberg, Germany)

**Nur77, a new target to boost DC vaccination?**

Speaker: Marleen Ansems (Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands)

**Zoledronic Acid suppresses tumour associated macrophages and myeloid derived suppressor cells in murine HCC**

Speaker: Misbah Aslam (University Medical Center of the Johannes Gutenberg-University, Mainz, Germany)

**HPN424, a half-life extended, PSMA/CD3-specific TriTAC for the treatment of metastatic prostate cancer**

Speaker: Richard J. Austin (Harpoon Therapeutics, South San Francisco, United States)

**Identification of exceptional therapeutic anti-CD40 agonists by optimal exploitation of rabbit antibody diversity through single B-cell cloning**

Speaker: Karsten Beckmann (MAB Discovery GmbH, Neuried, Germany)

**Identification of a naturally presented myeloma-associated BCMA peptide as an immunogenic T-cell epitope for immunotherapeutic approaches**

Speaker: Tatjana Bilich (University of Tübingen, Institute for Cell Biology, Tübingen, Germany)

**Citrullination: a mechanism to rapidly alert the immune system to cellular stress**

Speaker: Victoria Brentville (Scancell Ltd, Nottingham, United Kingdom)

**Citrullinated peptides from self-antigens can be presented by HLA-DP4 and can be targeted for tumor therapy**

Speaker: Victoria Brentville (Scancell Ltd, Nottingham, United Kingdom)

**CD8+ T cell immunity against phosphopeptide neoantigens and its potential use for monitoring checkpoint inhibitor therapy**

Speaker: Nico Buettner (Medical Center University of Freiburg, Faculty of Medicine, Freiburg, Germany)

**Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients**

Speaker: Luigi Buonaguro (Istituto Nazionale Tumori Pascale, Napoli, Italy)

**Selective FcγR engagement by CTLA-4 antibodies results in increased functional activity**

Speaker: John Castle (Agenus Inc, Lexington, United States)

**Mass spectrometry-based antigen discovery expands the cancer immunopeptidome**

Speaker: Chloe Chong (Ludwig Center for Cancer Research, Epalinges, Switzerland)

**Survivin, WT1 and SSX2: new targets for the immunotherapy of adult B-acute lymphoblastic leukaemia**

Speaker: Leah Cooksey (The University of Hull, Hull, United Kingdom)

**Cell-intrinsic and spatially distant tumor PD-L1 alters local and global anti-tumor immunity and responses to anti-PD-L1 or anti-PD-1 through novel chemokine and TIL effects**

Speaker: Tyler Curiel (UT Health San Antonio, San Antonio, United States)

**A novel aryl hydrocarbon receptor antagonist (PX-A24590) with anti-tumor activity in a syngeneic mouse pancreatic cancer model**

Speaker: Ulrich Deuschle (Phenex Pharmaceuticals AG, Heidelberg, Germany)

**Comprehensive characterization of IL-15-based tumor targeted Immunocytokines**

Speaker: Laura Dix (Glycotope GmbH, Berlin, Germany)

**Engineering novel antibody-based therapeutics for targeting of tumor endothelial marker 1 (TEM1)**

Speaker: Julie Katrin Fierle (Ludwig Institute for Cancer Research at the University of Lausanne, Epalinges, Switzerland)

**RIG-I agonist acts synergistically with PD1-checkpoint blockade as combinatorial immunotherapy in a model of hepatocellular carcinoma**

Speaker: Simone Formisano (Klinikum der Universität München, Munich, Germany)

**The immunopeptidomic landscape of primary versus recurrent disease in glioblastoma**

Speaker: Lena Katharina Freudenmann (University of Tübingen, Interfaculty Institute for Cell Biology, Tübingen, Germany)

**Tumor antigen-dependent T cell activation and tumor localization induced by a novel 4-1BB x 5T4 ADAPTIR™ bispecific antibody**

Speaker: Sara Fritzell (Alligator Bioscience AB, Lund, Sweden)

**Decoding the HLA immunopeptidome: Elucidating patterns of HLA allotype association and malignant cells**

Speaker: Michael Ghosh (University of Tübingen, Tübingen, Germany)

**Targeting the signal peptide in MMTV-associated breast cancer**

Speaker: Jacob Hochman (The Hebrew University of Jerusalem, Jerusalem, Israel)

**Development of an optimized scaffold for bispecific T cell receptor therapeutics**

Speaker: Martin Hofmann (Immatics biotechnologies GmbH, Tuebingen, Germany)

**Rapamycin and Zoledronic Acid strongly inhibit growth of advanced murine hepatocellular carcinoma via activation of innate and adaptive immunity**

Speaker: Muhammad Ashfaq Khan (University Medical Center of the Johannes Gutenberg-University, Mainz, Germany)

**Cytomegalovirus stimulates angiogenesis and emerges as a druggable target in glioblastoma**

Speaker: Harald Krenzlin (Gutenberg-Universität Mainz, Mainz, Germany)

**Immunopeptidomic profiling of triple negative breast cancer identifies potential immunotherapy target antigens**

Speaker: Demin Li (University of Oxford, Oxford, United Kingdom)

**The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation**

Speaker: Anne Månsson Kvarnhammar (Alligator Bioscience, Lund, Sweden)

**Anticancer immunity mediated by the novel hexavalent human GITR agonist HERA-GITRL is conveyed by activating T cells without affecting Treg cells**

Speaker: Viola Marschall (Apogenix AG, Heidelberg, Germany)

**KY1055: a novel ICOS/PD-L1 bispecific antibody, enhances T cell activation and delivers potent monotherapy anti-tumour responses in vivo**

Speaker: Matthew McCourt (Kymab, Cambridge, United Kingdom)

**Detection of novel citrullinated targets for cancer therapy**

Speaker: Rachael Metheringham (Scancell Limited, Nottingham, United Kingdom)

**Identification of receptor binding partners via APEX2 proximity labeling**

Speaker: Bastian Meyer (Klinikum der Universität München, Medizinische Klinik und Poliklinik II, München, Germany)

**Identification and characterization of HLA-Ligands for immunotherapeutic approaches in oropharyngeal squamous-cell carcinoma**

Speaker: Lena Mühlenbruch (University of Tübingen, Tübingen, Germany)

**T cells against the N345K mutation of PIK3CA**

Speaker: Julia Neufeld (Johannes Gutenberg University Medical Center, Mainz, Germany)

**Human IL-10 (AM0010, Pegilodecakin) in combination with immune checkpoint blockade**

Speaker: Martin Oft (ARMO BioSciences, Redwood City, United States)

**Establishment of a human CD3ε transgenic mouse model to assess anti-tumor efficacy of human T-cell-redirecting bispecific antibodies**

Speaker: Davy Xuesong Ouyang (Crown Bioscience Inc., Santa Clara, United States)

**DSP106 - a novel PD1-CD70 dual signaling protein (DSP) for cancer immunotherapy**

Speaker: Yehudith Jitka Sagiv (Kahr Medical Ltd, Jerusalem, Israel)

**Human endogenous retroviruses as a potential reservoir for T cell mediated cancer immunotherapy**

Speaker: Sunil Kumar Saini (Technical University of Denmark, Lyngby, Denmark)

**Depletion of intratumoural regulatory T cells by the anti-ICOS antibody KY1044 in combination with immune checkpoint blockade enhances the anti-tumour response in pre-clinical models.**

Speaker: Richard Sainson (Kymab, Cambridge, United Kingdom)

**Glyco-engineering of an anti-CD40 antibody enhances its agonistic activity**

Speaker: Phillip Schiele (Glycotope GmbH, Berlin, Germany)

**Database matching of de novo sequencing candidates - a new strategy for MHC peptide identification**

Speaker: Andreas Schlosser (Universität Würzburg, Würzburg, Germany)

**HERA-LIGHT, a novel hexavalent HVEM agonist promoting T cell activation and expansion**

Speaker: Julian P. Sefrin (Apogenix AG, Heidelberg, Germany)

**Theranostic tumor imaging of neuroblastoma using radiolabeled  $\alpha$ CD276-antibody**

Speaker: Dominik Sonanini (Eberhard Karls University of Tübingen, Tübingen, Germany)

**Expression data integration: advancing immuno-oncology target discovery**

Speaker: Frank Staubli (NEBION AG, Zurich, Switzerland)

**Setup and validation of a T cell receptor maturation platform resulting in high-affinity binders for engineering of bispecific molecules**

Speaker: Felix Unverdorben (Immatics biotechnologies GmbH, Tuebingen, Germany)

**Tumour glycan-targeting monoclonal antibodies - Candidate immunogenic cell death inducers**

Speaker: Mireille Vankemmelbeke (Scancell Ltd, Nottingham, United Kingdom)

**Preclinical development of CD37CAR T-cell therapy for treatment of B-cell non-Hodgkin lymphoma**

Speaker: Sébastien Wälchli (Oslo University Hospital, Oslo, Norway)

**Cloning, expression and functional characterization of an HLA-C\*07:01-restricted  $\alpha\beta$  T-cell receptor against chondroitin sulfate proteoglycan 4 (CSPG4)**

Speaker: Catherine Wölfel (Internal Medicine III, Mainz, Germany)

**GARP expressing platelets and the induction of peripheral tolerance: A novel target for anti-tumor-therapy?**

Speaker: Niklas Zimmer (University Medical Center Mainz, Mainz, Germany)

Short Talk Session  
15:45 - 16:15

Gutenberg Hall A

**Meet the Editor**

**An editors guide to scientific publishing**

**15:45 - 16:15**

Speaker: Priscilla Kelly (Science Magazine, Washington, DC, United States)

CIMT Members Meeting  
17:30 - 19:00

Dijon Room

**General Members Assembly of the Association for Cancer Immunotherapy CIMT**

19:30 - 24:00

Foyer

**Social Event & Poster Award Ceremony**

Plenary Session  
08:30 - 10:00

Congress Hall

### Immunoguiding

Chair: Marij J.P. Welters (Leiden University Medical Center, Leiden, Netherlands)  
Chair: Sine Reker Hadrup (Technical University of Denmark, Copenhagen, Denmark)

**Reprogramming the tumor microenvironment for efficient cancer immunotherapy** **08:30 - 09:00**

Speaker: Günter J. Hämmerling (German Cancer Research Center DKFZ, Heidelberg, Germany)

**Complement in cancer: untangling an intricate relationship** **09:00 - 09:30**

Speaker: Dimitrios Mastellos (National Center for Scientific Research 'Demokritos', Athens, Greece)

**Lung cancer evolution and immune escape** **09:30 - 10:00**

Speaker: Nicholas McGranahan (Cancer Research UK Lung Cancer Centre of Excellence, London, United Kingdom)

Break  
10:00 - 10:30

Foyer

### Coffee Break

Plenary Session  
10:30 - 12:30

Congress Hall

### Regulatory Research organized by CIMT-RRG and CARAT

Chair: Ulrich Kalinke (TWINCORE, Hanover, Germany)  
Chair: Christian Buchholz (Paul-Ehrlich-Institut, Langen, Germany)

**Chimeric antigen receptor (CAR) modified T cells - EU regulatory considerations** **10:30 - 11:10**

Speaker: Martina Schüssler-Lenz (Committee for Advanced Therapies (CAT), European Medicines Agency, London, United Kingdom)

**From Karl Landsteiner to CAR-T cells: from processes to products and patients** **11:10 - 11:50**

Speaker: Martin Hildebrandt (Technical University Munich, Munich, Germany)

**Translation of CAR-based innovations into clinics: how to overcome the regulatory hurdles** **11:50 - 12:30**

Speaker: Bernd Schröder (Miltenyi Biotech, Teterow, Germany)

Short Talk Session  
10:30 - 11:45

Gutenberg Hall A

### Short Talk Session IV Therapeutic Vaccination

Chair: Sebastian Kreiter (TRON, Mainz, Germany)  
Chair: Kris Thielemans (Vrije Universiteit Brussel, Brussels, Belgium)

<b>Bifunctional RNA-nanoparticles to enhance dendritic cell activation and enable MRI-based detection of dendritic cell migration to lymph nodes</b>	<b>10:30 - 10:45</b>
Speaker: Adam Grippin (University of Florida Brain Tumor Immunotherapy Program, Gainesville, United States)	
<b>Enrichment of gene modified cellular melanoma vaccines with melanoma stem cells or inducible pluripotent stem cells increases immunogenicity and clinical effectiveness in mice</b>	<b>10:45 - 11:00</b>
Speaker: Andrzej Mackiewicz (Poznań University of Medical Sciences, Poznań, Poland)	
<b>Local radiotherapy and E7-RNA-LPX vaccination activate non-redundant mechanisms and lead to complete tumor rejection of well-established HPV16+ TC-1 tumors</b>	<b>11:00 - 11:15</b>
Speaker: Nadja Salomon (TRON, Mainz, Germany)	
<b>NKG2A blockade potentiates CD8+ T-cell immunity induced by cancer vaccines</b>	<b>11:15 - 11:30</b>
Speaker: Thorbald van Hall (Leiden University Medical Center, Leiden, Netherlands)	
<b>Biomaterial-based scaffolds improve delivery of therapeutic nanoparticle cancer vaccines to dendritic cells</b>	<b>11:30 - 11:45</b>
Speaker: Jorieke Weiden (Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands)	

Short Talk Session  
10:30 - 11:45

Gutenberg Hall B

### Short Talk Session V Immunomonitoring

Chair: Cecile Gouttefangeas (University of Tübingen, Tübingen, Germany)  
Chair: Dimitrios Mastellos (National Center for Scientific Research 'Demokritos', Athens, Greece)

<b>High dimensional analysis of the myeloid cell landscape in human breast cancer metastatic lymph nodes</b>	<b>10:30 - 10:45</b>
Speaker: Rodrigo Nalio Ramos (Institute Curie, Paris, France)	
<b>The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival</b>	<b>10:45 - 11:00</b>
Speaker: Saskia J.A.M. Santegoets (Leiden University Medical Center, Leiden, Netherlands)	
<b>Empty MHC class I molecules: An alternate, convenient, and improved detection tool for antigen specific T cells</b>	<b>11:00 - 11:15</b>
Speaker: Tripti Tamhane (Technical University of Denmark, Lyngby, Denmark)	
<b>Immunomonitoring for personalized cancer immunotherapies via ex vivo combinatorial workflow and concurrent high-resolution class I &amp; II ICS</b>	<b>11:15 - 11:30</b>
Speaker: Alexander Ulges (Immatic Biotechnologies GmbH, Tübingen, Germany)	
<b>Disappearance of NY-ESO-1 and Melan-A-specific T-cells from peripheral blood is associated with clinical response in melanoma patients undergoing anti-PD-1 therapy</b>	<b>11:30 - 11:45</b>
Speaker: Henning Zelba (University Medical Center Tübingen, Tübingen, Germany)	

Short Talk Session  
11:45 - 13:00

Gutenberg Hall A

### Short Talk Session VI Improving Immunity

Chair: Mustafa Diken (TRON, Mainz, Germany)  
Chair: Onur Boyman (University Hospital Zurich, Zurich, Switzerland)

<b>Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable treatment of solid tumors with T cell therapies</b>	<b>11:45 - 12:00</b>
Speaker: Riikka Havunen (University of Helsinki, Helsinki, Finland)	
<b>Intratumoral RNA treatment: a promising approach for the therapy of solid tumors</b>	<b>12:00 - 12:15</b>
Speaker: Katja Fiedler (CureVac AG, Tübingen, Germany)	
<b>Human interleukin-2 (IL-2)/anti-IL-2 antibody complexes preferentially stimulate effector cells and show strong efficacy in tumor models</b>	<b>12:15 - 12:30</b>
Speaker: Andreas Katopodis (Novartis Institutes of Biomedical Research, Basel, Switzerland)	
<b>Activin-A protects against lung cancer progression by potentiating anti-tumor immunity</b>	<b>12:30 - 12:45</b>
Speaker: Ioannis Morianos (Biomedical Research Foundation of the Academy of Athens, Athens, Greece)	
<b>Loss of myeloid cell GCN2 drives progression in experimental melanomas during immune checkpoint inhibition</b>	<b>12:45 - 13:00</b>
Speaker: Jana K. Sonner (German Cancer Research Center DKFZ, Heidelberg, Germany)	

Short Talk Session  
11:45 - 13:00

Gutenberg Hall B

### Short Talk Session VII Clinical Trials

Chair: Anthony Kong (University of Birmingham, Birmingham, United Kingdom)

Chair: Stephan Grabbe (University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany)

<b>HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients</b>	<b>11:45 - 12:00</b>
Speaker: Luigi Buonaguro (Istituto Nazionale Tumori Pascale, Napoli, Italy)	
<b>CetuGEX and Cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC) - p16+ subgroup analysis of the phase 2 RESGEX study</b>	<b>12:00 - 12:15</b>
Speaker: Beate Habel (Glycotope GmbH, Berlin, Germany)	
<b>The safety, tolerability, and preliminary clinical activity of the CXCR4 inhibitor X4P-001 and nivolumab in renal cell carcinoma patients that are refractory to nivolumab monotherapy</b>	<b>12:15 - 12:30</b>
Speaker: Tracy L. Rose (Lineberger Comprehensive Cancer Center, Chapel Hill, United States)	
<b>High rate of objective anti-tumor response in 9 patients with primary or recurrent glioblastoma after viro-immunotherapy with oncolytic parvovirus H-1 in combination with bevacicumab and PD-1 checkpoint blockade</b>	<b>12:30 - 12:45</b>
Speaker: Karsten Geletneky (Klinikum Darmstadt, Darmstadt, Germany)	
<b>Human IL-10 (AM0010, Pegilodecakin) in combination with immune checkpoint blockade</b>	<b>12:45 - 13:00</b>
Speaker: Martin Oft (ARMO BioSciences, Redwood City, United States)	

Break  
13:00 - 14:00

Foyer

### Lunch

## **Therapeutic Vaccination**

Chair: Hans-Georg Rammensee (University of Tübingen, Tübingen, Germany)

Chair: Carl Figdor (Radboud University Medical Center, Nijmegen, Netherlands)

### **Dendritic cell-based vaccination against cancer**

**14:00 - 14:30**

Speaker: Jolanda de Vries (Radboud University Medical Center, Nijmegen, Netherlands)

### **Personalized RNA vaccines**

**14:30 - 15:00**

Speaker: Özlem Türeci (German Cluster of Individualized ImmunIntervention (CI3), Mainz, Germany)

### **Therapeutic cancer vaccine for combination with immune checkpoint blockade therapy: formulation matters**

**15:00 - 15:30**

Speaker: Yared Hailemichael (MD Anderson Cancer Center, Houston, United States)